Diuretics are among the most frequently used drugs to treat hypertension, congestive heart failure, edema, and play a role in the prevention of some forms of recurrent nephrolithiasis [1] [2] [3] . Most commonly used diuretics act by directly inhibiting tubular transport processes such as the loop diuretics blocking the Na dapagliflozin, and empagliflozin) primarily reducing proximal tubular glucose absorption causing osmotic diuresis [4] [5] .
The use of diuretics from the first group directly blocking salt reabsorption can be limited by hypo-or hyperkalemia or hypercalcemia. In CKD patients with increasingly lower GFR, the efficacy of drugs can be reduced requiring escalating doses or alternative drugs. The indication for SGLT2 inhibitors and vasopressin receptor antagonists are distinct and currently mostly restricted to the treatment of type 2 diabetes, ADPKD, or hyponatremic syndromes, respectively. Moreover, the efficacy of diurectics blocking salt absorptive pathways is often limited by the plasticity of the renal tubule and its ability to stimulate the growth and activity of downstream segments contributing to treatment-resistant hypertension 3, 6 . Then combinations of diuretics acting in subsequent segments and on distinct pathways may help to improve diuretic efficacy.
The collecting duct is the last site of salt reabsorption and contributes to up to Since salt absorption by the collecting duct is influenced by salt delivery, the role of pendrin in compensating for reduced salt absorption by earlier segments has been studied. On the one hand, chronic inhibition of NCC activity with thiazides increases pendrin expression whereas on the other hand concomitant genetic ablation of NCC and pendrin causes a severe syndrome of renal salt loss and volume depletion 8, 12 . Similarly, deletion of NCC and the NDBCE transporter working in conjunction with pendrin leads also to salt wasting 13 . Taken together, the biology of pendrin and its interactions with other salt transporting pathways make pendrin an attractive target for novel inhibitors that may be useful as diuretics standing alone or used in combination with existing drugs to enhance their efficacy.
Alan Verkman and colleagues identified novel compounds selectively inhibiting pendrin with high affinity using a functional chemical library screen 14 . As reported here in this issue of JASN, these compounds given to mice had per se no effect on diuresis or acid-base parameters in urine and blood. However, when given in combination with furosemide, pendrin inhibitors potentiated the diuretic effect of furosemide. Importantly, the pendrin inhibitor even further increased diuresis in mice given chronically furosemide. On the other hand, mice treated with hydrochlorothiazide plus pendrin inhibitor showed a paradoxical reduction in diuresis 15 .
Several issues are of major interest and some questions remain open. Next to tests of safety and pharmacokinetics in humans, the question remains whether pendrin inhibitor will have a similar diuretic potency in humans as in rodents. The relative number of pendrin expressing cells may be relatively lower in human kidney compared to rodent kidney and may thus limit its efficacy [16] [17] .
Next to kidney, pendrin (SLC26A4) is expressed in various other organs including thyroid glands, inner ear, adrenal glands, and airways which will impact on its side effects as well modulate its diuretic and anti-hypertensive effects. While pendrin function in inner ear and thyroid glands may be problematic and may cause side effects, the inhibition of adrenal gland pendrin may add to the beneficial effects of pendrin blockade in kidney. Pendrin function in adrenal glands appears to support aldosterone secretion and inhibition may help to reduce renal salt reabsorption as well as other extrarenal effects of aldosterone, e.g. in heart and vasculature for NaCl absorption. NDBCE may also be targeted by thiazides whereas pendrin can be blocked by novel inhibitors.
